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Peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RARs), members of the nuclear receptor
superfamily, are transcription factors that regulate a variety of important cellular functions. PPARs form heterodimers retinoid
X receptor (RXR), an obligate heterodimeric partner for other nuclear receptors. Several novel links between retinoid metabolism
and PPAR responses have been identiﬁed, and activation of PPAR/RXR expression has been shown to increase response to
retinoids. PPARγ has emerged as a key regulator of cell growth and survival, whose activity is modulated by a number of
synthetic and natural ligands. While clinical trials in cancer patients with thiazolidinediones (TZD) have been disappointing,
novel structurally diﬀerent PPARγ ligands, including triterpenoids, have entered clinical arena as therapeutic agents for epithelial
and hematopoietic malignancies. Here we shall review the antitumor advances of PPARγ, alone and in combination with RARα
ligands in control of cell proliferation, diﬀerentiation, and apoptosis and their potential therapeutic applications in hematological
malignancies.
1.Introduction
Acute myelogenous leukemia (AML) remains incurable in
most patients because of the likelihood of relapse and the
development of resistant disease [1]. Many novel agents do
not improve survival of patients once relapse occurs, which
enforces the need for more eﬀective treatment strategies for
AML exploiting apoptosis and/or diﬀerentiation induction.
Ligands of nuclear hormone receptors (NHRs) have
been shown to induce apoptosis and/or inhibiting prolifer-
ation in a variety of preclinical models. The most striking
improvement in AML therapy was achieved by the treatment
of acute promyelocytic leukemia (APL) using the retinoic
acid (RA) receptor- (RAR-) speciﬁc ligand, all-trans RA
(ATRA) [2, 3]. ATRA, combined with chemotherapy, results
in complete remission (CR) rates ranging from 72% to 90%
in APL patients with the oncogenic transcriptional repressor
PML-RARα [4–8]. However, approximately 10% to 30%
of patients relapse [8] and frequently develop resistance to
ATRA [9, 10]. Acquisition of speciﬁc mutations in the ligand
binding site, which leads to altered interactions with tran-
scriptional coregulators, is a well-documented mechanism
of acquired ATRA resistance [11, 12]. In addition, several
alternative mechanisms such as DNA methylation [13]o r
impaired telomerase regulation [14] have been proposed to
cause ATRA-resistant disease.
Considering the potential of using PPARγ ligands in APL
“transcriptional” therapy, this paper summarizes the eﬀects
of endogenous and synthetic PPARγ ligands in AML and
focuses on elucidating the mechanisms underlying the anti-
tumor eﬀects of novel synthetic PPARγ ligand 2-cyano-3,12-
dioxooleana-1,9-dien-28-oic acid (CDDO) in APL.
2. PPARγ andPPARγ Ligands
PPARs belong to the NHR superfamily of ligand-dependent
transcription factors, which includes RAR and RXR among





Figure 1: Molecular structure of CDDO 2-cyano-3,12-
dioxooleana-1,9-dien-28-oic acid (CDDO).
PPARα,a n dP P A R β/δ.P P A R γ exists as a heterodimer with
RXR, and upon activation by endogenous or synthetic
ligands, PPARγ/RXR binds to the speciﬁc response elements
PPRE in the promoter regions of target genes, respectively,
which in turn functions as a transcription factor [15–17].
PPARγ m o d u l a t e sg e n en e t w o r k si n v o l v e di nc o n t r o l -
ling growth, cellular diﬀerentiation, and apoptosis [18].
PPARγ receptor can be activated by endogenous ligands
(e.g., prostaglandin D2 (PGD2), 15-deoxy prostaglandin J2
(15dPGJ2), or 15-hydroxyeicosatetraenoic acid (15-HETE))
[19,20],andsyntheticligandsthatincludeinsulinsensitizing
antidiabetic thiazolidinediones (TZD); troglitazone (TGZ),
rosiglitazone (RGZ), ciglitazone (CGZ), or pioglitazone
(PGZ) [21–23]; nonsteroidal anti-inﬂammatory compounds
indomethacin, ibuprofen, ﬂufenamic acid, or fenoprofen
[24]; triterpenoids 2-cyano-3,12-dioxooleana-1,9-dien-28-
oic acid (CDDO) [25]a r eas e m i s y n t h e t i ct r i t e r p e n o i d
derived from oleanolic acid, whose structure contains two
α, β-unsaturated carbonyl moieties. CDDO was shown to
release nuclear receptor corepressor (NCoR) and recruit
CCAAT/enhancer-binding protein (CBP/p300) to PPARγ
[25]( Figure 1).
PPARγ ligands induce diﬀerentiation and inhibit prolif-
eration in several tumor models [26–34]. The regulation of
gene transcription by ligand-bound PPARγ involves cofactor
proteins, which bridge transcription factors to the basal
transcriptional machinery or modify chromatin structure.
These include release of small accessory molecules known as
corepressors (e.g., NCoR or silencing mediator for retinoid
receptor and thyroid hormone receptors (SMRT)) and
recruitment ofcoactivators(e.g.,CBP/p300, cyclicadenosine
monophosphate response-element binding protein (CREB),
steroid receptor coactivator-1 (SRC-1), receptor interact-
ing protein 140(RIP140), or PPARγ interacting protein
(PRIP/RAP250) [35–40]. The multiprotein complex induces
transcription by chromatin remodeling and interaction with
the basal transcriptional machinery [41, 42], and the relative
levels of cofactor expression (e.g., availability of cofactors
CBP/p300 versus SRC-1) also control the speciﬁcity of the
physiological response to target gene transcription [43].
3. Antitumor Effects of PPARγ inAML
High PPARγ expression was observed in normal bone
marrow and peripheral blood CD34+ progenitor cells [44].
Furthermore, signiﬁcantly higher PPARγ mRNA expression
was observed in primary AML cases compared to normal
peripheral blood or bone marrow mononuclear cells [45,
46].
The mechanisms of cell diﬀerentiation and cell cycle
arrestbyactivatedPPARγ dependheavilyonthespeciﬁcityof
PPARγ ligands.Theinductionofdiﬀerentiationbyactivation
of PPARγ may represent a promising novel therapeutic
approachforcancerasalreadydemonstratedforliposarcoma
[27] and in xenograft models of prostate [47] and colon
cancer [30]. Diﬀerentiation therapy may well play a role
in acute myeloid leukemias, analogous to ATRA-induced
diﬀerentiationinAPL.PPARγ isknowntobeinducedand/or
expressed in cells of the myeloid/monocytic lineage [48, 49].
In PPARγ expressing AML cell lines, PPARγ ligand TGZ
suppressed their clonal growth with G1 cell cycle phase
arrest,induceddiﬀerentiationintomonocytes,andincreased
apoptosis at higher concentrations [50, 51]. Troglitazone-
induced G0/G1 cell cycle arrest with upregulation of p21
mRNA in myeloid leukemia cell lines [52]. In concert with
these ﬁndings, PPARγ ligand PGZ and 15dPGJ2 suppressed
proliferation, and the combined treatment with ATRA
synergistically induced myeloid diﬀerentiation in promyelo-
cytic leukemia NB4 cells [53]. Furthermore, simultaneous
treatment with TGZ and RXR or RAR ligands resulted in
additive suppression of growth indicating that PPARγ ligand
combined with a retinoid is a potent inhibitor of clonogenic
growth of AML [50]. CDDO has been reported to induce
monocytic diﬀerentiation of human myeloid leukemia cells
and adipogenic diﬀerentiation of mouse ﬁbroblasts [54].
CDDO-Me also induced granulo-monocytic diﬀerenti-
ation in primary AML cells and cell lines. Combinations
with ATRA or the RXR-speciﬁc ligand LG100268 enhanced
the eﬀects of CDDO-Me on cell viability and/or terminal
diﬀerentiation of myeloid leukemic cell lines [54]. CDDO-
Me-induced enhanced apoptosis when combined with ara-
C and retinoids indicating potential activity in the future
therapy for AML [55].
With respect to the mechanisms of PPARγ-ligand-
induced diﬀerentiation, CCAAT enhancer-binding protein
alpha (CEBPA) translational upregulation has been reported
to be required for CDDO-induced granulocytic diﬀer-
entiation of AML patients samples and cell lines [56].
CDDO increases the ratio of transcriptionally active p42
and the inactive p30 CEBPA isoform, which in turn leads
to transcriptional activation of CEBPA-regulated genes and
associates with dephosphorylation of eIF2alpha and phos-
phorylation of eIF4E [56].
PPARγ ligands are additionally known to induce apop-
tosis. The mechanisms of apoptosis induction by activated
PPARγ depend heavily on the speciﬁcity of PPARγ ligands.
PPARγ activation by natural ligand 15dPGJ2 and synthetic
ligandTGZinduceapoptosisaccompaniedbycaspase-3acti-
vation and downregulated c-myc gene expression in myeloid
leukemic cells [57]. 15dPGJ2 and TGZ have been alsoPPAR Research 3
reported to induce upregulation of bax and downregulation
of antiapoptotic proteins survivin and bcl-2 in AML and
CML [58]. Furthermore, downregulation of cyclooxygenase-
2 expression, disruption of mitochondrial membrane poten-
tial, activation of caspase-3, downregulation of Bcl-2, Bcl-
Xl, and Mcl-1, and upregulation of Bax by these PPARγ
agonists 15dPGJ2 and TGZ has been reported in human
monocytic leukemia cells [59]. Semisynthetic oleanane
triterpenoid CDDO has potent diﬀerentiating, antiprolifer-
ative, anti-inﬂammatory, and apoptosis-inducing properties
[54]. CDDO has been reported to activate caspase-8 and
-3 and to induce mitochondrial cytochrome c release in
leukemic cells and in osteosarcoma cells [60–62]. CDDO
has been further shown to activate the intrinsic pathway of
apoptosis that involves the release of cytochrome c and AIF
and initiates caspase-dependent and independent cell death
in AML [63]. The C-28 methyl ester of CDDO, CDDO-
Me [55], and C-28 imidazolide imide of CDDO (CDDO-
Im) [64] has been shown to be more potent than CDDO
in inducing apoptosis and diﬀerentiation of acute myeloid
leukemia (AML) cells. CDDO-Me is 3- to 5-fold more active
than CDDO in inhibiting the viability of AML cells in an
MDR-1- and p53-independent manner, inducing apoptosis
through a loss of mitochondrial membrane potential, and
increasing caspase-3 cleavage and proapoptotic Bax protein.
It has signiﬁcantly less cytotoxicity against normal CD34+
progenitor cells, assuring therapeutic window [55].
In addition, CDDO was shown to inhibit NF-
κB-mediated gene expression in leukemic cells [62].
CDDO/tumor-necrosis-factor- (TNF-) induced apoptosis
occurs through selective inhibition of NF-κB-dependent
antiapoptotic proteins, bypassing potential mitochondrial
resistance mechanisms [62]. CDDO-Me also inhibits both
constitutive and inducible NF-κB through inhibition of IκB
α kinase, leading to the suppression of expression of NF-
κB-regulated gene products and enhancement of apoptosis
induced by TNFα [65].
Notably,certainPPARγ ligandsexecuteanti-tumoractiv-
ities without requiring interaction with the PPAR ligand
binding domain [66]. For example, CDDO, CDDO-Me, and
CDDO-Im activate PPARγ-dependent and -independent
pathways that inhibit cancer-cell growth [67]. They acti-
vate PPARγ in transactivation assays, and CDDO-induced
apoptosis was diminished by dominant-negative PPARγ in
myeloid HL-60 cells and by T007 in myeloid U937 cells [68],
but CDDO-Im-induced diﬀerentiation in leukemia cells was
not inhibited by the PPARγ antagonist GW9662 [61], and
T007 did not aﬀect inhibition of SKOV3 ovarian cancer
cell growth by CDDO [69]. In these scenarios, interaction
with the PPARγ receptor is irrelevant to the anti-cancer
eﬀects, which may depend on cell type, presence/activity
of the receptor(s), and cellular abundance of coactiva-
tors/corepressors. PPAR-independent eﬀects of PPARγ lig-
andsaredueinparttotheirelectrophilicnature,proteasomal
degradation of cell cycle-, and apoptosis-regulatory proteins,
transcriptional repression, and other mechanisms [70–72].
Both, PPARγ-dependent and -independent pathways that
contribute to inhibition of cancer cell growth may be
beneﬁcial for cancer chemotherapy [67].
4. Antitumor Effects of PPARγ-Active
Triterpenoid CDDO on APL
RARs bind with high aﬃnity to the RA-responsive element
(RARE)asaheterodimerwithRXR,whichalsoheterodimer-
izes with other nuclear receptors, such as PPARγ.
In APL cells, the oncogenic transcription factor PML-
RARα, a dominant negative transcriptional repressor, targets
consist of two copies of an AGGTCA, a highly conserved
consensus for RARα. PML-induced dimerization allows the
two RARα moieties of PML-RARα to bind very distant
monomeric DNA sites. The spectrum of response elements
for PML-RARα and PML-RARα-RXR (DR1-DR16 response
elements) is much broader than one for the wild-type RAR-
RXR(DR1,DR2,andDR5),andPML-RARα-RXRoligomers
silence a wide range of nuclear receptor target genes [73].
X-RARα fusion proteins in APL have been demonstrated
to negatively aﬀect transactivation of PPARγ [74], indicating
that inhibition of PPARγ activity may contribute to the
pathophysiologyofthediﬀerentiation blockinAPL,andthat
PPARγ ligands could sensitize APL cells to the diﬀerentiating
eﬀects of ATRA including ATRA-resistant cells [45].
PML-RARαrecruits the nuclear corepressors and histone
deacetylase (HDAC), which leads to histone condensation
and transcriptional repression [75–77]. ATRA acts by caus-
ing the PML-RARα/HDAC complex to dissociate, thereby
converting PML-RARα into a transcriptional activator [76].
Reactivation of ATRA target genes by inducing an appro-
priate level of histone acetylation in their promoters is a
potential strategy for restoring anticancer eﬀects of ATRA in
refractory APL [77]. Diﬀerentiating agents including ATRA,
arsenic, cAMP, HDAC inhibitors, and rexinoids relieve this
repression through various molecular mechanisms, allowing
spontaneous diﬀerentiation of leukemic blasts [73].
In fact, it has been demonstrated that HDAC inhibitors
(HDACI) such as trichostatin A (TSA), sodium phenylbu-
tyrate (PB), and suberoylanilide hydroxamic acid (SAHA)
can augment the cell growth inhibition induced by ATRA,
and that ATRA combined with SAHA increased survival and
induced remissions in APL transgenic mice harboring the
PLZF-RARα translocation [78]. In addition, the PML-RARα
fusion protein was observed to induce hypermethylation on
RAR promoter, and the DNA methyltransferase inhibitor 5-
asa-2-deoxycytidine (5-Aza-dC) enhanced ATRA-induced
RAR promoter transactivation in APL cells [13].
Induction of APL cell diﬀerentiation by ATRA is asso-
ciated with modulation of several critical genes, including
RARβ2 [78], C/EBPβ [79], p21 [80], PU.1 [81], or a domi-
nantrepressorofRARsignalingPRAME[82].Notably,PML-
RARα has a signiﬁcant aﬃnity for DR1 [83], a binding site
for RXR/PPARγ heterodimers, and negatively contributes to
transactivation by ligand-activated PPRE.
The RA-target gene RARβ plays a crucial role in medi-
ating the growth-inhibitory and tumor suppressive eﬀects
of retinoids in various cancer cells [84–87], and RARβ
is silenced in many tumors [84, 87, 88]a n dm y e l o i d
leukemias [89, 90] including APL [13]. Its upregulation
has been proposed as a general mechanism of retinoid-







































Figure 2: CDDO augments ATRA-induced reactivation of RARβ2 in APL via histone acetylation. Combination of all-trans RA (ATRA)
and 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) increases H3-Lys9 acetylation in RARβ P2 and RARβ2 transcription. CDDO-
bound PPARγ may recruit coactivator proteins, including CBP-p300 and SRC-1 to PPARγ/RXR, which in turn induce histone acetylation
and reactivation of ATRA target genes. Ac: acetylated histone H3-Lys9, HDAC: histone deacetylase, mSin3: mammalian homolog of the
S. cerevisiae corepressor, Sin 3, NCoR: nuclear receptor corepressor, SRC-1: steroid receptor coactivator-1, CBP/p300: CCAAT/enhancer-
binding protein, PCAF: P300/CBP-associated factor.
[72]. RARβ2 induction has been implicated in several tumor
cell models in which retinoids inhibit growth and induce
diﬀerentiation [91]. In HeLa cells, the transfected RARβ2
transgene inhibits proliferation, while exogenous RA further
increases the ability of the transgene to inhibit proliferation
[92]. Disruption of RARβ2 expression in RARβ2p o s i t i v e
cancercellsabolishesRAeﬀectsofgrowtharrest[72],andthe
presence of RARβ2 antisense predisposed the murine lung
tissue to tumor formation [91].
Semisynthetic PPARγ ligand triterpenoid CDDO aug-
mented the ATRA-induced reactivation of RARβ2i nA P L
via histone acetylation [93]. In combination with ATRA,
CDDO may activate the transcription of PPARγ target
genes, which in turn increase the aﬃnity of RARβ for
βRARE. CDDO caused a prominent increase in RARβ2
binding to the response element in the gel shift assay, and
ATRA/CDDO combination increased H3-Lys9 acetylation
in RARβ P2 and RARβ2 transcription [93]. These ﬁndings
support the concept that ligation of the PPARγ and RAR
nuclear receptors is capable of inducing cell maturation
and enhances proapoptotic eﬀects of ATRA in APL cells.
PPARγ and RXR form a complex with βRARE in the
RARβ promoter, and the combination of ligands of PPARγ
and RXR was reported to induce RARβ in ATRA-resistant
breast cancer cells in the presence of histone deacetylase
inhibitor [94]. Based on these ﬁndings, CDDO may induce
recruitment of PPARγ/RXR to the RARE, which promotes
aﬃnity of RARβ for βRARE.
Ligand-bound RAR/RXR heterodimer has been shown
to recruit the histone acetylase PCAF and the coactivator
CBP/p300, which accumulates the HAT activity on the
heterodimer/DNA complex and ﬁnally leads to enhanced
retinoid-responsive transcription [95]. Likewise, the regula-
tion of gene transcription by ligand-bound PPARγ involves
the recruitment of coactivator proteins, including CBP/p300
and SRC-1 [17, 25, 39, 40]. CDDO has been shown to
induce transactivation and PPARγ interaction with multiple
coactivators including SRC-1, SRC-2, SRC-3, TRAP 220,
CARM-1, and PGC-1 in colon cancer cells [67]. While
CDDO alone did not recruit CBP to the RARβ2p r o m o t e r ,
the CDDO/ATRA combination increased ATRA-induced
CBP recruitment. Altogether, the ability of ATRA/CDDO to
restore RAR signaling and to cause cell maturation might
be in part dependent on the PPARγ-mediated induction of
histone acetylation and reactivation of ATRA target genes
(Figure 2).
ATRA is a nonselective retinoid capable of transacti-
vating both, RARα and RXR receptors [96, 97]. Although
PPARγ/RXR heterodimers promote transcriptional activity
of PPARγ [16], RXR-selective ligand LG100268 and CDDO
combination was not suﬃcient for RARβ2 induction, sug-
gesting that RARβ2 gene induction is not due to ligand-
induced RXR activation in APL cells [93].
Whereas CDDO alone failed to induce maturation of
APL cells, the combination of CDDO with ATRA induced
ATRA sensitive- and resistant-APL cells to diﬀerentiate into
mature granulocytes with striking increase in Nitro Blue
Tetrazolium (NBT) reduction positive and CD11b-positive
cells above eﬀects elicited by single agent ATRA [93].
Furthermore,thecombineduseofCDDOderivativeCDDO-
Me and ATRA in the murine model of APL resulted in the
signiﬁcant increase of mature granulocytic cells in peripheral
blood and prolongation of survival compared to the single
compound treatment of ATRA or CDDO. Ikeda et al. [64]
also demonstrated that CDDO-Im selectively downregulated
expression of PML-RARα fusion protein with an activation
of caspase 8, which might contribute to enhanced ATRA-
induced diﬀerentiation in APL cells, and arsenic-trioxide-PPAR Research 5
(ATO-) induced apoptosis in both ATRA-sensitive NB4 and
resistant R2 cell lines and primary APL cells.
RAsignalingisacommonmechanisminAMLotherthan
APL, and HDAC inhibitors have been shown to restore RA-
dependent transcriptional activation and trigger terminal
diﬀerentiation of primary blasts from AML patients [89].
Recent reports of in vivo diﬀerentiationoftheleukemicclone
following HDAC inhibitor valproic acid/ATRA treatment in
AML patients [98] further suggest the possibility that the
ATRA/CDDO or its more potent derivatives combination
may be useful transcriptional/diﬀerentiation therapy in non-
APL AML. Randomized trial AML HD98B showed that
administration of ATRA in addition to intensive chemother-
apy improved the outcomes of the patients with genotype of
“mutant (mt-) NPM1 without FLT3-ITD” [99]. NPM1 has
been reported to be a possible transcriptional corepressor
[100]. Inhibition of NPM1 oligomerization or knockdown
of NPM1-induced apoptosis and sensitized to ATRA in mt-
NPM1-bearing AML cells [101]. These ﬁndings suggest new
avenues of exploration for ATRA and CDDO derivatives
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